Surgical Endoscopy

, Volume 24, Issue 9, pp 2351–2353 | Cite as

Monitoring and assessing the intraabdominal therapeutic response for gastric cancer: is second-look laparoscopy the solution?

Letter
  • 50 Downloads

Notes

Disclosures

Odysseas Zoras and John Spiliotis no conflicts of interest or financial ties to disclose.

References

  1. 1.
    Inoue K, Nakane Y, Michiura T, Yamaki S, Yui R, Sakuramoto K, Iwai A, Tokuhara K, Araki Y, Kim S, Nakai K, Sato M, Yamamichi K, Kwon AH (2009) Feasibility and accuracy of second-look laparoscopy after gastrectomy or gastric cancer. Surg Endosc 23:2307–2313CrossRefPubMedGoogle Scholar
  2. 2.
    Van Cutsem E, Kang Y, Chung H et al (2009) Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 27(Suppl):18s. Abstract LBA4509Google Scholar
  3. 3.
    Roukos DH (2010) Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 17:14–17CrossRefPubMedGoogle Scholar
  4. 4.
    Roukos DH (2004) Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol 11:127–129CrossRefPubMedGoogle Scholar
  5. 5.
    Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality-of-life improvement and challenges for improving long-term outcomes. Ann Surg 250:349–350CrossRefPubMedGoogle Scholar
  6. 6.
    Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22:1553–1555CrossRefPubMedGoogle Scholar
  7. 7.
    Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651CrossRefGoogle Scholar
  8. 8.
    Briasoulis E, Liakakos T, Dova L et al (2006) Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 6:931–939CrossRefPubMedGoogle Scholar
  9. 9.
    Roukos DH (2009) Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol 16:795–798CrossRefPubMedGoogle Scholar
  10. 10.
    Kappas AM, Roukos DH (2002) Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol 9:828–830CrossRefPubMedGoogle Scholar
  11. 11.
    Roukos DH, Paraschou P, Lorenz M (2000) Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. Ann Surg Oncol 7:719–726CrossRefPubMedGoogle Scholar
  12. 12.
    Ziogas D, Polychronidis A, Kanellos I, Roukos D (2009) Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? Ann Surg 249:695–696CrossRefPubMedGoogle Scholar
  13. 13.
    Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22:1405–1406CrossRefPubMedGoogle Scholar
  14. 14.
    Stratton MR, Campbell PJ, Futreal PA (2009) The cancer genome. Nature 458:719–724CrossRefPubMedGoogle Scholar
  15. 15.
    Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenge s towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 9:1413–1416CrossRefPubMedGoogle Scholar
  16. 16.
    Roukos DH (2009) Mea culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn 9:217–221CrossRefPubMedGoogle Scholar
  17. 17.
    Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16:2678–2681CrossRefPubMedGoogle Scholar
  18. 18.
    Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360:1362, author reply 1363CrossRefPubMedGoogle Scholar
  19. 19.
    Roukos DH, Lykoudis E, Liakakos T (2008) Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 26:4360–4361CrossRefPubMedGoogle Scholar
  20. 20.
    Ziogas D, Baltogiannis G, Fatouros M, Roukos DH (2008) Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg 247:714–715CrossRefPubMedGoogle Scholar
  21. 21.
    Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16:1771–1782CrossRefPubMedGoogle Scholar
  22. 22.
    Roukos DH (2009) Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 16:772–773CrossRefPubMedGoogle Scholar
  23. 23.
    Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian Knot”? Ann Surg Oncol 16:774–775CrossRefPubMedGoogle Scholar
  24. 24.
    Roukos DH (2008) Breast-cancer stromal cells with TP53 mutations. N Engl J Med 358:1636PubMedGoogle Scholar
  25. 25.
    Roukos DH (2009) Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol 27:1337–1338CrossRefPubMedGoogle Scholar
  26. 26.
    Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249:1067–1068CrossRefPubMedGoogle Scholar
  27. 27.
    Roukos DH (2009) Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn 9:227–229CrossRefPubMedGoogle Scholar
  28. 28.
    Roukos DH (2009) Genome-wide association studies: how predictable is a person’s cancer risk? Expert Rev Anticancer Ther 9:389–392CrossRefPubMedGoogle Scholar
  29. 29.
    Roukos DH (2009) Assessing both genetic variation (SNPs/CNVs) and gene–environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn 9:1–6CrossRefPubMedGoogle Scholar
  30. 30.
    Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10(3):247–250CrossRefPubMedGoogle Scholar
  31. 31.
    Roukos DH (2010) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3):283–287CrossRefPubMedGoogle Scholar
  32. 32.
    Roukos DH (2007) Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357(2):1555–1556PubMedGoogle Scholar
  33. 33.
    Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358(2):197; author reply 198Google Scholar
  34. 34.
    Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128CrossRefPubMedGoogle Scholar
  35. 35.
    Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn 10(1):33–48CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of General Surgery, University Hospital of Heraklion, Medical School University of Crete Heraklion, Crete Greece
  2. 2.Department of SurgeryMetaxa Cancer Hospital Piraeus Greece

Personalised recommendations